FI20096188A0 - Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle - Google Patents

Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle

Info

Publication number
FI20096188A0
FI20096188A0 FI20096188A FI20096188A FI20096188A0 FI 20096188 A0 FI20096188 A0 FI 20096188A0 FI 20096188 A FI20096188 A FI 20096188A FI 20096188 A FI20096188 A FI 20096188A FI 20096188 A0 FI20096188 A0 FI 20096188A0
Authority
FI
Finland
Prior art keywords
nutrigenetic
biomarkers
obesity
diabetes
type
Prior art date
Application number
FI20096188A
Other languages
English (en)
Swedish (sv)
Inventor
Jukka Salonen
Original Assignee
Mas Metabolic Analytical Servi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mas Metabolic Analytical Servi filed Critical Mas Metabolic Analytical Servi
Priority to FI20096188A priority Critical patent/FI20096188A0/fi
Publication of FI20096188A0 publication Critical patent/FI20096188A0/fi
Priority to PCT/FI2010/050923 priority patent/WO2011058232A1/en
Priority to US13/509,903 priority patent/US20120225047A1/en
Priority to EP10829581.7A priority patent/EP2501826A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI20096188A 2009-11-16 2009-11-16 Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle FI20096188A0 (fi)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20096188A FI20096188A0 (fi) 2009-11-16 2009-11-16 Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle
PCT/FI2010/050923 WO2011058232A1 (en) 2009-11-16 2010-11-16 Nutrigenetic biomarkers for obesity and type 2 diabetes
US13/509,903 US20120225047A1 (en) 2009-11-16 2010-11-16 Nutrigenetic biomarkers for obesity and type 2 diabetes
EP10829581.7A EP2501826A4 (en) 2009-11-16 2010-11-16 NUTRIGENETIC BIOMARKERS FOR ADIPOSITAS AND TYPE-2 DIABETES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20096188A FI20096188A0 (fi) 2009-11-16 2009-11-16 Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle

Publications (1)

Publication Number Publication Date
FI20096188A0 true FI20096188A0 (fi) 2009-11-16

Family

ID=41395235

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20096188A FI20096188A0 (fi) 2009-11-16 2009-11-16 Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle

Country Status (4)

Country Link
US (1) US20120225047A1 (fi)
EP (1) EP2501826A4 (fi)
FI (1) FI20096188A0 (fi)
WO (1) WO2011058232A1 (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
WO2013006736A1 (en) * 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
US8765377B2 (en) 2011-10-13 2014-07-01 Boston Heart Diagnostics Corporation Compositions and methods for treating and preventing coronary heart disease
WO2014047388A1 (en) 2012-09-21 2014-03-27 Ethicon Endo-Surgery, Inc. Systems and methods for predicting metabolic and bariatric surgery outcomes
US10242756B2 (en) 2012-09-21 2019-03-26 Ethicon Endo-Surgery, Inc. Systems and methods for predicting metabolic and bariatric surgery outcomes
EP2898101A4 (en) 2012-09-21 2016-08-03 Ethicon Endo Surgery Inc CLINICAL PREDICTORS FOR WEIGHT LOSS
US20140120559A1 (en) * 2012-10-26 2014-05-01 Boston Heart Diagnostics Corporation Diabetes panel
US20150362491A1 (en) * 2013-01-14 2015-12-17 The General Hospital Corporation Methods and assays relating to rnf216
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
CN107075562B (zh) * 2014-09-30 2021-09-24 深圳华大基因科技有限公司 用于肥胖症相关疾病的生物标记物
EP3220810A4 (en) 2014-11-17 2018-05-16 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity
CN105441551A (zh) * 2015-12-26 2016-03-30 上海中优生物高科技有限责任公司 荷尔蒙失调型肥胖基因个体化干预组合物制备方法及系统
CN105420377A (zh) * 2015-12-26 2016-03-23 上海中优生物高科技有限责任公司 高胰岛素型肥胖基因个体化干预组合物制备方法及其系统
CN105624288A (zh) * 2016-03-16 2016-06-01 上海中优生物高科技有限责任公司 毒素堆积型肥胖基因个体化干预组合物及制备方法和系统
CN106978474A (zh) * 2016-08-17 2017-07-25 上海易瑞生物科技有限公司 一种2型糖尿病易感基因检测分型试剂盒及其应用
US20180144820A1 (en) 2016-10-24 2018-05-24 Habit, Llc System and method for implementing meal selection based on vitals, genotype and phenotype
CN112362785B (zh) * 2020-11-19 2022-12-27 南京工业大学 一组诊断标志物在诊断精索静脉曲张所致弱精子症中的应用
CN112863675B (zh) * 2021-03-17 2021-09-07 南通市第一人民医院 一种骨质疏松患者的信息收集与评估方法及系统
CN112980945B (zh) * 2021-04-28 2022-04-15 广东省科学院微生物研究所(广东省微生物分析检测中心) 一种利用神经网络模型预测低碳饮食减重干预效果的方法
CN115576856B (zh) * 2022-12-08 2023-04-11 浪潮通信信息系统有限公司 能耗评估方法及装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2006053955A2 (en) * 2004-11-19 2006-05-26 Oy Jurilab Ltd Method and kit for detecting a risk of essential arterial hypertension
CA2592176A1 (en) * 2004-12-09 2006-06-15 Perlegen Sciences, Inc. Markers for metabolic syndrome obesity and insulin resistance
US7901885B2 (en) * 2006-05-09 2011-03-08 Dsm Ip Assets B.V. Genes and markers in type 2 diabetes and obesity
EP2177615A1 (en) * 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases

Also Published As

Publication number Publication date
US20120225047A1 (en) 2012-09-06
EP2501826A1 (en) 2012-09-26
EP2501826A4 (en) 2013-07-10
WO2011058232A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
FI20096188A0 (fi) Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
BRPI0920069A2 (pt) biomarcadores
DE602009000328D1 (de) Parallelmechanismus
DK2106215T3 (da) Brød med forhøjet arabinoxylo-oligosaccharid-indhold
BRPI0913515A2 (pt) fechamento com mecanismo limitador
DK2252395T3 (da) Afsvovlingsmaterialer
BRPI0907637A2 (pt) Biomarcadores p53
BRPI0820557A2 (pt) biomarcadores diagnósticos de diabetes
DK2448758T3 (da) Serigrafitrykning
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
BRPI0913513A2 (pt) fechamento com mecanismo limitador
EP2265642A4 (en) BIOMARKERS
DK3514173T3 (da) DKK-1-antistoffer
DE602008001148D1 (de) Messinstrument
EP2263086A4 (en) BIOMARKERS
DK2382224T3 (da) Metalhydracid-materialer
DK2278899T3 (da) Bryggemekanisme
GB0818660D0 (en) Biomarkers
GB0807214D0 (en) Biomarkers
EP2265641A4 (en) BIOMARKERS
GB0821912D0 (en) Biomarkers
EP2157092A4 (en) MEANS FOR THE TREATMENT OF DIABETES
BRPI0909909A2 (pt) caderno de composição
FR2950528B1 (fr) Composition amincissante

Legal Events

Date Code Title Description
FD Application lapsed